Regenxbio Shares Rise After Report FDA Will Reverse Rejection of Rare-Disease Drug
Regenxbio (RGNX) shares surged as much as 37% in premarket trading after the Wall Street Journal reported that the FDA has agreed to reverse its rejection of the company's rare-disease treatment. This development could lead Regenxbio to refile for approval.
Tickers: $RGNX
Topics: biotech drug approvals stock movement